WO2004064814A1 - Improvements in or relating to anti-aromatase composition - Google Patents

Improvements in or relating to anti-aromatase composition Download PDF

Info

Publication number
WO2004064814A1
WO2004064814A1 PCT/US2003/001207 US0301207W WO2004064814A1 WO 2004064814 A1 WO2004064814 A1 WO 2004064814A1 US 0301207 W US0301207 W US 0301207W WO 2004064814 A1 WO2004064814 A1 WO 2004064814A1
Authority
WO
WIPO (PCT)
Prior art keywords
range
aromatase
dose
capsule
contain
Prior art date
Application number
PCT/US2003/001207
Other languages
French (fr)
Inventor
Michael Donald Farley
Original Assignee
Michael Donald Farley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Donald Farley filed Critical Michael Donald Farley
Priority to EP03702128A priority Critical patent/EP1624863A1/en
Priority to AU2003203012A priority patent/AU2003203012A1/en
Priority to PCT/US2003/001207 priority patent/WO2004064814A1/en
Publication of WO2004064814A1 publication Critical patent/WO2004064814A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond

Definitions

  • This testosterone/ estrone ratio will exert a powerful and considerable reactions to the emotional well being, as well as in sexual functions, libido, muscle mass and strength, energy, cardiovascular health, bone integrity and memory behavior.
  • testosterone/ estrogen ratio is directly influenced by the aromitazation and bioavailable levels of several other hormones, including DHEA projesterone, androstenedione, estrone aldosterone, cortisol, estradiol and dihydrotestoasterone.
  • DHEA projesterone androstenedione
  • estrone aldosterone cortisol
  • estradiol estradiol
  • dihydrotestoasterone dihydrotestoasterone.
  • These hormones which directly effect testosterone and estrogen ratios also directly effect emotional well being, as well as sexual function, libido, muscle mass, fat to lean muscle ratios, strength, energy, cardiovascular health, osteoporosis, memory and cognitive function, as well as risk for breast cancer and benign prostate hypertrophy. It is well established, that as a human being ages, these testosterone/ estrone ratios adjust and change with age, with increasing formation levels of estrone and a proportional decrease in the formation of testosterone.
  • the present invention includes an anti-aromatase pharmaceutical or more specifically a nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Uritica dioica) 16:1 in the range of about 275 mg. to about 350 mg; b: Pumpkin seed oil (cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to
  • the present invention also relates to a totally new use of a male hormone panel aromatasition structure with an androgen pathway as depicted at Table I and II, also for breast cancer and other related treatments. 10 TABLE I
  • Tables I and II depict Aromatisation structure that are beneficial to the method of treatment of various ailments, for example, benign prostate hyperfhrophy, some forms of breast cancer, and in the treatment of osteoporsis, etc.
  • the present invention relates to a totally new application of several naturally occurring aromatase inhibitors which interupt several stages in the presented hormone panel (Table I), which illustrates the currently accepted normal aromatization sequence.
  • This invention also incorporates for the first time, an inhibitor of sex hormone binding globulin which allows bioavailable hormone to remain active at target tissue sites for a longer period of time.
  • the present invention includes an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 g.; c.
  • this invention is an anti-aromatase capsule or dose in commpound form in which the pharmaceutical or nutraceutical composition consists of: a. Pumpkin seed oil (Cucubita pepo) of about 175 mg; b. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg.
  • this invention resides in an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550
  • the present invention is an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical or nutraceutical composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
  • the invention resides in a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase pharmaceutical or nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Urtica dioica) 16:1 in the range of about 275 mg. to above 350 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 g.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg.
  • the invention provides a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention assists a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituting an anti- aromatase capsule or dose compound form in which the composition for the maintenance of testosterone/ estrone ratios with the anti-aromatase composition being characterized by: . a pumpkin seed oil (cucubita pepo) of about 175 mg.; b. Nettle root extract (uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 g.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention also includes a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical composition consists of: a. Pygeum Africanum (prunus africana) bark extract standardized to contain 13% total sterols and about 25 g.; b. Pumpkin seed oil (cucubita pepo) of about 175 mg.; c. Nettle root extract (urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention furthermore includes a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (urtica dioica) of about 300 mg.; c. Pumpkin seed oil (cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
  • An anti-aromatase pharmaceutical composition consisting of in capsule or dose to contain:
  • Nettle root extract (Urtica dioica) 16:1 in the range of about 275 to 350 mg.
  • Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg.
  • Pygeum Africanum (Prunus africana) bark extract standardized to contain at least 12 to 15% of total sterols in the range of about 20 to 40 mg. and Chrysin in the range of 475 to 550 mg.
  • This pharmaceutical composition assists in the treatment of b enign prostate hyperthropy and breast cancer etc.

Abstract

An anti-aromatase pharmaceutical composition, consisting of in capsule or dose to contain: Nettle root extract (Urtica dioica) 16:1 in the range of about 275 to 350 mg; Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg; Pygeum Africanum (Prunus africana) bark extract standardized to contain at least 12 to 15 % of total sterols in the range of about 20 to 40 mg; and Chrysin in the range of 475 to 550 mg. This pharmaceutical composition assists in the treatment of benign prostate hypertropy and breast cancer etc.

Description

Improvements In Or Relating To Anti- Aromatase Composition
It is known, that throughout life of a mammal or a human being, testosterone/ estrone ratios do have a considerable effect on mammal or human life.
This testosterone/ estrone ratio will exert a powerful and considerable reactions to the emotional well being, as well as in sexual functions, libido, muscle mass and strength, energy, cardiovascular health, bone integrity and memory behavior.
It is advantageous that testosterone/ estrogen ratio is directly influenced by the aromitazation and bioavailable levels of several other hormones, including DHEA projesterone, androstenedione, estrone aldosterone, cortisol, estradiol and dihydrotestoasterone. These hormones which directly effect testosterone and estrogen ratios, also directly effect emotional well being, as well as sexual function, libido, muscle mass, fat to lean muscle ratios, strength, energy, cardiovascular health, osteoporosis, memory and cognitive function, as well as risk for breast cancer and benign prostate hypertrophy. It is well established, that as a human being ages, these testosterone/ estrone ratios adjust and change with age, with increasing formation levels of estrone and a proportional decrease in the formation of testosterone.
It is known from the specification of U.S. Patent No. 4,598,072 to Schweibert etal dated July 1, 1986 to provide for an aromatase inhibitor and an antiandrogen which generally is applicable for the treatment of prostatic hyperglania, incorporated herein by reference only.
Furthermore, it is known from the specification of U.S. Patent No. 5,972,921 to Santti etal dated October 26, 1999 in the use of an aromatase inhibitor aclministered for the specific treatment for men for detrusor wrethral dyssynergia. This is incorporated herein for reference only.
It is also known from the specification of U.S. Patent No. 5,861,389 to Racilrnaier etal dated January 19, 1999 for specific treatment of only androgen deficiency in men using selective aromatase inhibitors. This is incorporated herein for reference only.
The present invention includes an anti-aromatase pharmaceutical or more specifically a nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Uritica dioica) 16:1 in the range of about 275 mg. to about 350 mg; b: Pumpkin seed oil (cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to
5 about 40 mg; and d. Chrysin in the range of about 475 mg. to about 550 mg. However, the present invention also relates to a totally new use of a male hormone panel aromatasition structure with an androgen pathway as depicted at Table I and II, also for breast cancer and other related treatments. 10 TABLE I
Figure imgf000003_0001
TABLE II Normal Range of Hormone Values
Figure imgf000003_0002
Both Tables I and II depict Aromatisation structure that are beneficial to the method of treatment of various ailments, for example, benign prostate hyperfhrophy, some forms of breast cancer, and in the treatment of osteoporsis, etc.
Specifically, the present invention relates to a totally new application of several naturally occurring aromatase inhibitors which interupt several stages in the presented hormone panel (Table I), which illustrates the currently accepted normal aromatization sequence. This invention also incorporates for the first time, an inhibitor of sex hormone binding globulin which allows bioavailable hormone to remain active at target tissue sites for a longer period of time. Suitably, the present invention includes an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 g.; c. Pygeu Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg. Conveniently, this invention is an anti-aromatase capsule or dose in commpound form in which the pharmaceutical or nutraceutical composition consists of: a. Pumpkin seed oil (Cucubita pepo) of about 175 mg; b. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg; and d. Chrysin in the range of about 475 mg. to about 550 mg. Advantageously, this invention resides in an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg. Moreover, the present invention is an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical or nutraceutical composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg. In addition, the invention resides in a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase pharmaceutical or nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Urtica dioica) 16:1 in the range of about 275 mg. to above 350 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 g.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg. Also, the invention provides a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
Furthermore, the invention assists a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituting an anti- aromatase capsule or dose compound form in which the composition for the maintenance of testosterone/ estrone ratios with the anti-aromatase composition being characterized by: . a Pumpkin seed oil (cucubita pepo) of about 175 mg.; b. Nettle root extract (uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 g.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
The invention also includes a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical composition consists of: a. Pygeum Africanum (prunus africana) bark extract standardized to contain 13% total sterols and about 25 g.; b. Pumpkin seed oil (cucubita pepo) of about 175 mg.; c. Nettle root extract (urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg. The invention furthermore includes a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (urtica dioica) of about 300 mg.; c. Pumpkin seed oil (cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
An anti-aromatase pharmaceutical composition, consisting of in capsule or dose to contain:
Nettle root extract (Urtica dioica) 16:1 in the range of about 275 to 350 mg.
Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg.
Pygeum Africanum (Prunus africana) bark extract standardized to contain at least 12 to 15% of total sterols in the range of about 20 to 40 mg. and Chrysin in the range of 475 to 550 mg.
This pharmaceutical composition assists in the treatment of b enign prostate hyperthropy and breast cancer etc.

Claims

ClaimsWhat we claim is....
1. An anti-aromatase pharmaceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: (a) Nettle root extract (ustica dioica) 16:1 in the range of about 275 to above 350 mg.;
(b) Pumpkin seed oil (cucubita pepo) in the range of about 150 mg. to about 205 mg.;
(c) Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14 % of total sterols in the range of about 20 mg. to about 40 mg.; and
(d) Chrysin in the range of about 475 mg. to about 550 mg.
2. An anti-aromatase capsule or dose in compound form as claimed in claim 1, characterized in that the pharmaceutical composition consists of: (a) Nettle root extract (Uritica dioica) 16:1 of about 300 mg.;
(b) Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.;
(c) Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14 % of total sterols in the range of about 20 mg. to about 40 mg.; and
(d) Chrysin in the range of about 475 mg. to about 550 mg.
3. An anti-aromatase capsule or dose in compound form as claimed in claim 1, characterized in that the pharmacuetical composition consists of: (a) Pumpkin seed oil (Cucubita pepo) of about 175 mg.;
(b) Nettle root extract (Uritica dioica) 16:1 of about 300 mg.;
(c) Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and (d) Chrysin in the range of about 475 mg. to about 550 mg.
An anti-aromatase capsule or dose in compound form as claimed in claim 1, characterized in that the pharmaceutical composition consists of:
(a) Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; (b) Pumpkin seed oil (Cucubita pepo) of about 175 mg.;
(c) Nettle root extract (Urtica dioica) 16:1 of about 300 mg; and
(d) Chrysin in the range of about 475 mg. to about 550 mg.
5. An anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical composition of which each capsule or dose consists of:
(a) Chyrsin of about 500 mg;
(b) Nettle root extract (Urtica dioica) of about 300 mg.;
(c) Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and
(d) Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
PCT/US2003/001207 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition WO2004064814A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03702128A EP1624863A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition
AU2003203012A AU2003203012A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition
PCT/US2003/001207 WO2004064814A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/001207 WO2004064814A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition

Publications (1)

Publication Number Publication Date
WO2004064814A1 true WO2004064814A1 (en) 2004-08-05

Family

ID=32769584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001207 WO2004064814A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition

Country Status (3)

Country Link
EP (1) EP1624863A1 (en)
AU (1) AU2003203012A1 (en)
WO (1) WO2004064814A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023161184A1 (en) * 2022-02-23 2023-08-31 Kevehazi Laura Mann Herbal composition for prostate health and prostate cancer prevention

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284873A (en) * 1991-07-11 1994-02-08 Laboratorios Madaus-Cerafarm, S.A. Pharmaceutical compositions derived from the acid fraction of lipid extracts of sabal serrulata, with adrenergic antagonist activity and method of preparing said composition
US5861389A (en) * 1994-09-22 1999-01-19 Schering Aktiengesellschaft Methods of treating androgen deficiency in men using selective aromatase inhibitors
US6039950A (en) * 1995-04-14 2000-03-21 University Of Southern California Pharmaceutical grade saw palmetto
US20010008638A1 (en) * 1999-07-14 2001-07-19 Brian J. Wilding Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284873A (en) * 1991-07-11 1994-02-08 Laboratorios Madaus-Cerafarm, S.A. Pharmaceutical compositions derived from the acid fraction of lipid extracts of sabal serrulata, with adrenergic antagonist activity and method of preparing said composition
US5861389A (en) * 1994-09-22 1999-01-19 Schering Aktiengesellschaft Methods of treating androgen deficiency in men using selective aromatase inhibitors
US6039950A (en) * 1995-04-14 2000-03-21 University Of Southern California Pharmaceutical grade saw palmetto
US20010008638A1 (en) * 1999-07-14 2001-07-19 Brian J. Wilding Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023161184A1 (en) * 2022-02-23 2023-08-31 Kevehazi Laura Mann Herbal composition for prostate health and prostate cancer prevention

Also Published As

Publication number Publication date
EP1624863A1 (en) 2006-02-15
AU2003203012A1 (en) 2004-08-13

Similar Documents

Publication Publication Date Title
Santos et al. Beyond tribulus (Tribulus terrestris L.): The effects of phytotherapics on testosterone, sperm and prostate parameters
Abd Jalil et al. Role of medicinal plants and natural products on osteoporotic fracture healing
Gonzales et al. Effects of different varieties of Maca (Lepidium meyenii) on bone structure in ovariectomized rats
Meissner et al. Therapeutic Effects of Pre-Gelatinized Maca (Lepidium peruvianum Chacon) used as a non-hormonal alternative to HRT in perimenopausal women-Clinical Pilot Study
US6346267B1 (en) Composition and method for treatment of symptoms associated with insufficient estrogen production
Keehn et al. Complementary and alternative medications for benign prostatic hyperplasia
Kim Phytotherapy: emerging therapeutic option in urologic disease
Zand et al. Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression
Mayo Black cohosh and chasteberry: herbs valued by women for centuries
US6607755B2 (en) Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
EP2705762B1 (en) Biologically active dietary supplement for normalizing the androgen level in men and the overall condition and reducing obesity
WO2004064814A1 (en) Improvements in or relating to anti-aromatase composition
Mayo A natural approach to menopause
WO2004064813A1 (en) Improvements in or relating to anti-aromatase composition
Zabłocka-Słowińska et al. Interactions between preparations containing female sex hormones and dietary supplements
WO2007141661A2 (en) Herbal compositions for the prevention or treatment of benign prostatic hyperplasia
Ogunlakin et al. Ameliorative effect of kigelia africana (Lam.) benth. fruit methanol extract in letrozole-induced polycystic ovarian syndrome rat
George et al. Acceptance of herbal medicines in andrology
EP3166614B1 (en) Composition for preventing and treating of tumors
WO2001087316A2 (en) Composition and method for increasing testosterone levels
Roeca et al. Menopause as a Manifestation of Aging
Kumari et al. New Emerging Aspect of Herbal Extracts for the Treatment of Osteoporosis: Overview
Geiselman et al. Nutritional Supplementation Approaches to Increase Testosterone Levels in Active Adult Males.
Stojanovska et al. The effect of complementary and alternative therapy at menopause: trick or treat
Chamawan et al. Effects of Pine Pollen Extract in Relieving Hot Flushes in Sex Hormone-Deficienct Rats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003702128

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003702128

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP